Retinalamin in diabetic retinopathy: three-month imaging and electrical responses
Comparison in people · 2024
- What was studied
- 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
- Main finding
- At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.
Ganglion-cell complex (GCL++) · 105.45 to 109.14 µm at month 3 · 103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline
Reported findings and study design
Patients received ten daily intramuscular injections or were followed without Retinalamin. The team used optical coherence tomography (OCT) and pattern and full-field electroretinography (ERG) at baseline, month 1 and month 3.
Population or model 56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
Dose, route and schedule
Ten daily intramuscular injections, with assessments at baseline and months 1 and 3. The papers leave the mass per injection unspecified. The earlier paper describes the Diopsys functional assessment in the same clinical groups.
Protocol source ↗ · Companion functional paper, confirmed cohort reuse in the later article
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Ganglion-cell complex (GCL++) | 105.45 to 109.14 µm at month 3 | 103.46 to 101.50 µm in controls · p = 0.047 for treated group versus baseline |
| Full-field ERG magnitude | 0.77 to 0.87 µV at month 3 | 0.91 to 0.88 µV in controls · p = 0.0489 for treated group versus baseline |
| Ganglion-cell and inner plexiform layers (GCL+) | 63.69 µm at baseline, 61.55 µm at month 1, 65.79 µm at month 3 | 65.04, 64.50 and 63.43 µm in controls |
Selected OCT and ERG means by visit
| Measure and group | Baseline | Month 1 | Month 3 | Month 3 vs baseline |
|---|---|---|---|---|
| GCL++ (µm), Retinalamin | 105.45 | 106.76 | 109.14 | p = 0.047 |
| GCL++ (µm), comparison | 103.46 | 102.81 | 101.50 | p unspecified |
| Nerve fiber layer (µm), Retinalamin | 41.66 | 43.10 | 43.41 | p = 0.048 |
| Nerve fiber layer (µm), comparison | 38.43 | 38.31 | 38.07 | p unspecified |
| Pattern ERG magnitude at 100% (µV), Retinalamin | 0.98 | 1.20 | 1.18 | p = 0.028 |
| Pattern ERG magnitude at 100% (µV), comparison | 1.27 | 1.26 | 1.26 | p unspecified |
| Full-field ERG magnitude (µV), Retinalamin | 0.77 | 0.85 | 0.87 | p = 0.0489 |
| Full-field ERG magnitude (µV), comparison | 0.91 | 0.92 | 0.88 | p unspecified |
The publication provides confidence intervals for arm means. The p values shown test change within the Retinalamin arm.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- The authors explicitly reuse the clinical groups from their earlier functional paper. These are two reports on one 56-person cohort.
- The groups start with different retinal electrical readings. The reported p values compare treated patients with their own baseline. The paper leaves group assignment, masking and the handling of measurements from both eyes unclear.
- These measures track retinal structure and electrical function. The data leave vision preservation and long-term disease progression unanswered.
Source details
Original journal report
Original Russian full article, Tables 1–2 and companion functional report.
Sources checked
Citation
Published
A. I. Malakhova, V. V. Strakhov, Y. A. Malakhova. Retinalamin in diabetic retinopathy: three-month imaging and electrical responses Vestnik Oftalmologii. 2024;140(5):97–104.
Study source ↗ · DOI 10.17116/oftalma202414005197 · Bibliography entry · Link to this summary